Real-world effectiveness of azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19 and pre-existing diabetes

Real-world effectiveness of azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19 and pre-existing diabetes

Summary: Azvudine and nirmatrelvir-ritonavir are prioritized treatments for SARS-CoV-2 infection in China, but their effectiveness and safety in hospitalized patients with COVID-19 and pre-existing diabetes remains unknown. In this retrospective cohort study, we collected 32,864 hospitalized COVID-1...

Full description

Saved in:

Bibliographic Details
Main Authors:	Guanyue Su, Silin Li, Donghua Zhang, Yongjian Zhou, Ling Wang, Yiqiang Yuan, Guowu Qian, Guotao Li, Na Han, Ming Cheng, Guangming Li, Shixi Zhang, Hong Luo, Mengzhao Yang, Yanyang Zhang, Zhan Song, Jiyuan Xing, Zujiang Yu, Zhigang Ren
Format:	Article
Language:	English
Published:	Elsevier 2025-02-01
Series:	iScience
Subjects:	Health sciences Medicine Medical specialty Immunology Endocrinology Pharmacology
Online Access:	http://www.sciencedirect.com/science/article/pii/S2589004225001671
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Efficacy and safety of azvudine versus nirmatrelvir/ritonavir in cancer patients with COVID-19
by: Bohan Jia, et al.
Published: (2025-03-01)

Effectiveness of azvudine versus nirmatrelvir/ritonavir for hospitalized patients with SARS-CoV-2 infection and pre-existing liver diseases
by: Guanyue Su, et al.
Published: (2025-05-01)

A retrospective cohort study of the efficacy and safety of oral azvudine versus nirmatrelvir/ritonavir in elderly hospitalized COVID-19 patients aged over 60 years
by: Bo Yu, et al.
Published: (2025-03-01)

Antiviral effectiveness and safety of azvudine in hospitalized SARS‐CoV‐2 patients with pre‐existing chronic respiratory diseases: A multicenter, retrospective cohort study
by: Junyi Sun, et al.
Published: (2025-04-01)

The Antiviral Efficacy and Safety of Azvudine in Hospitalized SARS‐CoV‐2 Infected Patients with Liver Diseases Based on a Multicenter, Retrospective Cohort Study
by: Junyi Sun, et al.
Published: (2025-04-01)

Effectiveness and safety of azvudine versus nirmatrelvir/ritonavir in hospitalized patients with COVID-19
by: Jin Yang, et al.
Published: (2025-05-01)

Concomitant and sequential administration of nirmatrelvir‐ritonavir and azvudine in patients with COVID‐19 caused by the Omicron variant: Safety and efficacy
by: Guang‐Bin Chen, et al.
Published: (2024-06-01)

The effectiveness and safety of azvudine treatment in COVID‐19 patients with kidney disease based on a multicenter retrospective cohort study
by: Bo Yu, et al.
Published: (2025-06-01)

Effectiveness and safety of azvudine versus nirmatrelvir-ritonavir in adult patients infected with COVID-19 omicron strains: a retrospective study in Beijing
by: Huaiya Xie, et al.
Published: (2024-10-01)

Real-world effectiveness and safety of oral azvudine versus Paxlovid in patients with COVID-19 and pre-existing hypertension: a multicentre, retrospective, cohort study in Henan Province, China
by: Ling Wang, et al.
Published: (2025-06-01)

Composite outcome of oral azvudine vs. nirmatrelvir-ritonavir in COVID-19 patients: a retrospective cohort study
by: Jingxia Chen, et al.
Published: (2025-04-01)

Immune development differs between preterm newborns fed mothers’ own milk and donor milk
by: Ziyang Tan, et al.
Published: (2025-07-01)

Effectiveness and Safety of Oral Azvudine for Elderly Hospitalized Patients With COVID‐19: A Multicenter, Retrospective, Real‐World Study
by: Ranran Sun, et al.
Published: (2025-04-01)

The relationship between metabolic syndrome and environmental endocrine disruptors: A systematic review and meta-analysis
by: Kai Pan, et al.
Published: (2025-07-01)

Tixagevimab/cilgavimab or placebo for COVID-19 in ACTIV-2: Safety, pharmacokinetics and neutralizing and anti-drug antibodies
by: Rachel A. Bender Ignacio, et al.
Published: (2025-03-01)

Effects of glucocorticoid withdrawal on relapse risk in systemic lupus erythematosus: A systematic review and meta-analysis
by: Sicheng Huang, et al.
Published: (2025-07-01)

Single-cell RNA-sequencing of circulating eosinophils from asthma patients reveals an inflammatory signature
by: Kyndal Goss, et al.
Published: (2025-06-01)

Adaptive immune responses against common viruses are sustained and functional in end-of-life patients
by: Anna Olofsson, et al.
Published: (2025-03-01)

Pharmacovigilance of Drug–Drug Interactions with Nirmatrelvir/Ritonavir
by: Victoria Hendrick, et al.
Published: (2024-10-01)

Factors influencing Nirmatrelvir/Ritonavir concentration in patients with COVID-19
by: Ping Xu, et al.
Published: (2024-12-01)

Segregation and integration of resting-state brain networks in a longitudinal long COVID cohort
by: Yuchen Zhang, et al.
Published: (2025-04-01)

Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in CKD Patients With COVID-19
by: Franco Wing Tak Cheng, et al.
Published: (2024-05-01)

Second generation CD2-targeting LFA-3 fusion protein SBT115301 to restore immune homeostasis in autoimmune disease
by: Herve Lebrec, et al.
Published: (2025-05-01)

Coronavirus replicase epitopes induce cross-reactive CD8 T cell responses in SARS-CoV-2-naive people with HIV-1
by: Katja G. Schmidt, et al.
Published: (2025-03-01)

Immune imprinting and antibody profiles to SARS-CoV-2 in urban and rural Ghana
by: Martin Montiel-Ruiz, et al.
Published: (2025-05-01)

Vasily Shervinsky ? Russian doctor, scientist, therapeutist and pathologist, Honored Scientist of the RSFSR AND THE FOUNDER OF THE RUSSIAN ENDOCRINOLOGY SCHOOL
by: N D Ivanova
Published: (2013-06-01)

Simultaneous Determination of Nirmatrelvir and Ritonavir in Human Plasma by HPLC-MS/MS
by: T. N. Komarov, et al.
Published: (2023-05-01)

Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19
by: Samuel Theodorus Sutanto, et al.
Published: (2023-01-01)

Optimized tacrolimus dosing strategy in kidney transplant recipients receiving nirmatrelvir-ritonavir for COVID-19
by: Han Yan, et al.
Published: (2025-01-01)

A Case Report of Severe Bradycardia Associated With Nirmatrelvir-ritonavir Drug-drug Interactions
by: Zhiqing Fu, et al.
Published: (2025-03-01)

Real-world effectiveness of simnotrelvir-ritonavir versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19 during the omicron wave in China: a retrospective cohort study
by: Chuntao Li, et al.
Published: (2025-07-01)

Glucose Levels in At-risk Newborns (GLEAN): a prospective cohort study on glucose profiles in infants at risk of hypoglycemia
by: Fabian Yap, et al.
Published: (2025-08-01)

Real-World Effectiveness of Bebtelovimab Versus Nirmatrelvir/Ritonavir in Outpatients with COVID-19
by: Christopher G. Rowan, et al.
Published: (2024-12-01)

Data mining of adverse drug event signals with Nirmatrelvir/Ritonavir from FAERS.
by: Ji Sun, et al.
Published: (2024-01-01)

Cardiovascular Drug Interactions with Nirmatrelvir/Ritonavir for COVID-19: Considerations for Daily Practice
by: Andrea Di Lenarda, et al.
Published: (2024-08-01)

Patient-specific therapeutic benefit of MuSK agonist antibody ARGX-119 in MuSK myasthenia gravis passive transfer models
by: Jamie L. Lim, et al.
Published: (2025-02-01)

Translating CD47-targeted therapy in gastrointestinal cancers: Insights from preclinical to clinical studies
by: Changgan Chen, et al.
Published: (2024-12-01)

Application of nirmatrelvir/ritonavir for the treatment of severe COVID-19 in a 3-year-old child
by: Xia Wang, et al.
Published: (2024-11-01)

Landscape of paediatric endocrine clinical practice in Italy: results from a survey of the Italian Society for Paediatric Endocrinology and Diabetology (ISPED)
by: Maria Elisabeth Street, et al.
Published: (2025-03-01)

Efficacy of Nirmatrelvir tablet/Ritonavir tablet in patients infected with COVID-19 aged 90 years and older
by: WEI Xueman, et al.
Published: (2025-05-01)